Primary Site >> Biliary tract Cancer
Gene >> ZHX2
|
|
|
|
|
|
|
|
|
|
|
|---|---|---|---|---|---|---|---|---|---|---|
|
Ref: Mutations of the BRAF gene in cholangiocarcinoma but not in hepatocellular carcinoma. PMID: 12692057 |
Ref: Tauroursodeoxycholate inhibits human cholangiocarcinoma growth via Ca2+-, PKC-, and MAPK-dependent pathways. PMID: 14701718 Ref: The V599E BRAF mutation is uncommon in biliary tract cancers. PMID: 15181454 Ref: Mutational analysis of BRAF in gallbladder carcinomas in association with K-ras and p53 mutations and microsatellite instability. PMID: 15221372 |
Ref: Effective palliation of advanced cholangiocarcinoma with sorafenib: a two-patient case report. PMID: 19089671 |
Ref: Sorafenib inhibits signal transducer and activator of transcription-3 signaling in cholangiocarcinoma cells by activating the phosphatase shatterproof 2. PMID: 19821497 |
Ref: Molecular targeted therapy of biliary tract cancer--results of the first clinical studies. PMID: 20388063 Ref: Effective treatment of advanced cholangiocarcinoma by hepatic arterial infusion chemotherapy combination with sorafenib: one case report from China. PMID: 20698202 |
Ref: Mutations in the RAS/RAF/MAP kinase pathway commonly occur in gallbladder adenomas but are uncommon in gallbladder adenocarcinomas. PMID: 21307665 Ref: Inhibitor of MEK1/2, selumetinib, for biliary tract cancer. PMID: 21910575 |
Ref: SWOG 0514: a phase II study of sorafenib in patients with unresectable or metastatic gallbladder carcinoma and cholangiocarcinoma. PMID: 21748296 Ref: CDK10 functions as a tumor suppressor gene and regulates survivability of biliary tract cancer cells. PMID: 22209942 |
Ref: Activation of mammalian target of rapamycin complex 1 (mTORC1) and Raf/Pyk2 by growth factor-mediated Eph receptor 2 (EphA2) is required for cholangiocarcinoma growth and metastasis. PMID: 23315987 Ref: PTEN loss and KRAS activation cooperate in murine biliary tract malignancies. PMID: 23483557 |
Ref: Molecular mechanism of cholangiocarcinoma carcinogenesis. PMID: 24895231 Ref: Dual Inhibition of PI3K-AKT-mTOR- and RAF-MEK-ERK-signaling is synergistic in cholangiocarcinoma and reverses acquired resistance to MEK-inhibitors. PMID: 25152244 |
Ref: Establishment of a patient-derived intrahepatic cholangiocarcinoma xenograft model with KRAS mutation. PMID: 26868125 Ref: The landscape of targeted therapies for cholangiocarcinoma: current status and emerging targets. PMID: 27102149 Ref: Impressive response to dual BRAF and MEK inhibition in patients with BRAF mutant intrahepatic cholangiocarcinoma-2 case reports and a brief review. PMID: 28078132 |
Ref: Arctigenin induced gallbladder cancer senescence through modulating epidermal growth factor receptor pathway. PMID: 28459363 Ref: A single-center experience of sorafenib monotherapy in patients with advanced intrahepatic cholangiocarcinoma. PMID: 28529557 Ref: Anti-tumor effects of NVP-BKM120 alone or in combination with MEK162 in biliary tract cancer. PMID: 29024814 Ref: Identification of MALT1 as both a prognostic factor and a potential therapeutic target of regorafenib in cholangiocarcinoma patients. PMID: 29371921 |